Second Gentleman Doug Emhoff has tested positive for COVID-19 after experiencing mild symptoms, his office announced Sunday, but his wife, Vice President Kamala Harris, has tested negative and remains asymptomatic
July 7, 2024, 2:25 PM ET
1 min read
WASHINGTON -- Second Gentleman Doug Emhoff has tested positive for COVID-19 after experiencing mild symptoms, his office announced Sunday, but his wife, Vice President Kamala Harris, has tested negative and remains asymptomatic.
Emhoff spokesperson Liza Acevedo said in a statement that the second gentleman is fully vaccinated and three times boosted and that he is currently asymptomatic, continuing to work remotely, and remaining away from others at home.
Acevedo said Harris was tested for COVID on Saturday out of an abundance of caution and the result was negative. She is scheduled to campaign in Las Vegas for President Joe Biden 's reelection on Tuesday.
Emhoff previously tested positive for COVID in March of 2022, and Harris tested positive for the virus the following month.
Biden tested positive for COVID in July of 2022, then tested positive again slightly more than three days after he was cleared to exit coronavirus isolation in a rare case of rebound following treatment with an anti-viral drug.
RALEIGH, N.C. New vaccines are on the horizon in North Carolina, just as COVID-19 cases are slightly up and schoolhouse doors are getting ready to reopen.
COVID-19 isnt getting more dangerous. Its getting more catchy, which makes sense, said Dr. David Wohl, an infectious disease physician with the UNC medical system.
However, the consequences of catching the virus are not the same as they were at the beginning of the pandemic.
For ... most of us, catching COVID-19 doesnt mean that we are going to end up on oxygen or a ventilator, Wohl said.
A Centers for Disease Control and Prevention-contracted wastewater testing site for Swain and Jackson counties revealed percentiles of COVID-19 ranging from 80-100% in the last two weeks.
Masking, handwashing and social distancing are all still regarded as great tools to stay well, but better indoor ventilation for cleaner air circulations is more of an emphasis, Wohl also said.
COVID-19 is not as deadly as it once was, because most people are immunized, either through infection or a vaccine, but the virus itself is equally, if not more transmissible, Wohl explained.
And there will be updated shots very soon that will target the variants circulating now, he said.
Wohl added this is good timing with year-round schools coming back from their shorter summer break.
How the virus is tracked in North Carolina is changing shape too and shifting away from state-run dashboards. Wohl said wastewater monitoring still provides a great tool for following how the virus may be changing.
Here, we systematically investigate the risk conferred by the presence and potential causal relevance of 1448 diseases for COVID-19 severity (hospitalisation, severe respiratory failure, and death) and Long COVID (Fig.1), based on medical disorder concepts14,16 defined and collated from >12 million medical records from primary (general practice), secondary care (hospital admissions), and disease registry (cancer registry), death certificates, and patient-reported conditions among 502,460 UKB participants (Fig.1 and Supplementary Data1). Incorporating primary care data more than doubled case numbers for more than half (n=817; 56.4%) of the diseases we considered (Supplementary Data1).
Scheme of the study design and analysis done, illustrating our workflow to define disease mechanisms that may causally contribute to severe COVID-19 or Long COVID. SNPs Single nucleotide polymorphisms; SPA = saddle point approximation; MAF = minor allele frequency; *COVID-19 HGI=COVID-19 Host Genetic Initiative, but excluding contributions from UK Biobank
We identified 1128 significant (p<1.1105) disease COVID-19 outcome associations, including almost half (n=679) of the diseases considered with at least one of the four COVID-19 outcomes derived (Fig.2 and Supplementary Data2). Pre-existing diseases were almost exclusively associated with a higher risk for COVID-19 endpoints (median hazard ratio (HR): 2.39, range: 0.5917.3), only two diseases (benign neoplasm of skin and varicella infection) were associated with a decreased risk. Associated diseases spanned almost all chapters of the ICD-10 (17 out of 18) but were consistently enriched in the chapters respiratory (odds ratio [OR]: 5.96; p-value: 2.7x108), circulatory (OR: 2.95; p-value: 3.5x107), and endocrine/metabolic diseases (OR: 2.76; p-value: 9.1104) when associated with severe COVID-19. In contrast, pre-existing disease-codes classified as symptoms were more than 13-fold enriched among diseases associated with an increased risk for Long COVID (OR: 13.2; p-value: 3.6x108) but also hospitalisation (OR: 5.53; p-value: 9.9x105) and death (OR: 3.06; p-value: 7.3x103).
Each panel contains association statistics, p-values (triangles), from Cox-proportional hazard models (two-sided) testing for an association between the disease on the x-axis and three different COVID-19 outcomes, as well as Long COVID. Disease associations passing the multiple testing correction (dotted line, p<1.1105) are depicted by larger triangles of which facing up ones indicate positive, e.g., increased disease risk, associations and downward facing vice versa. The diseases are ordered by ICD-10 chapters (colours) and the top ten for each endpoint annotated. Underlying sample numbers and statistics can be found in Supplementary Data1 and 2.
For COVID-19 requiring hospitalisation, we replicated and refined known associations with serious pre-existing diseases that have been previously used to identify clinically extremely vulnerable people. This included respiratory diseases like pseudomonal pneumonia (HR: 7.53, 95%-CI: 4.7411.97; p-value<1.2x1017), acute renal failure (HR: 4.02, 95%-CI: 3.744.32, p-value: <10300) or type 2 diabetes with renal complications (HR: 7.44; 95%-CI: 5.679.76; p-value: 1.5x1047), as well as immune deficiencies (e.g., deficiency of humoral immunity HR: 6.02; 95%-CI: 4.368.31; p-value: 1.3x1027) or patients under immune suppression (e.g., liver transplants HR: 7.25 95%-CI: 4.5111.68, p-value: 3.4x1016). However, we further observed strong associations with so far less recognized pre-existing mental health and psychiatric diseases and conditions with effect sizes comparable to those previously considered to identify extremely vulnerable people. This included symptoms of malaise and fatigue (HR: 2.17, 95%-CI: 2.072.27, p-value: 4.4x10222) or suicide attempts (HR 5.33, 95%-CI: 4.456.39, p-value: 3.6x1073). Most diseases (n=641, 95.5%, phetero>103) associated with similar magnitude across all three different definitions of COVID-19 severity, with different forms of dementias (phetero<2.1x1024) being among the few exceptions, associating with hospitalisation (HR: 3.83; 95%-CI: 3.384.34; p-value: 2.3x1097) and death (HR: 10.82; 95%-CI: 9.1512.80; p-value: 1.4x10170), but not severe respiratory failure (HR: 1.15; 95%-CI: 0.512.57; p-value: 0.74) due to COVID-19.
In contrast, pre-existing diseases associated with an increased risk for Long COVID only partially overlapped with those increasing the risk for severe COVID-19. Most notably, we replicated associations with anxiety disorders28 (HR: 2.59; 95%-CI: 2.093.20; p-value:1.8x1018) and other mental health symptoms, but most prominently with symptoms of malaise and fatigue (HR: 2.78; 95%-CI: 2.293.37; p-value:1.5x1025) that are hallmarks of Long COVID and were also strongly associated with severe COVID-19.
Almost all significant associations (99.8%, n=1126) were consistent when considering all-cause death as a competing event (Supplementary Data3), and more than half (63.6%; n=718) remained statistically significant (p<4.4x105) when accounting for a large set of potential confounders in multivariable Cox-models (Supplementary Data3). This suggests that potentially unreported associations, such as the increased risk for severe COVID-19 among patients reporting symptoms of malaise and fatigue (adjusted HR: 1.66, 95%-CI: 1.58 - 1.74, p-value=7.3x1092), are not just a reflection of a general disease burden or other chronic diseases associated with a greater risk for severe COVID-19.
We observed limited evidence for effect modifications by sex (n=7), non-European ancestry (n=1), or age (n=8), but not social deprivation, with 16 disease COVID 19 pairings showing evidence of significant differences (Supplementary Data4; p<3.6x106). All included stronger effects in women compared to men, e.g., gout for hospitalised COVID-19 (women: HR: 2.56, 95%-CI 2.212.96, p-value: 1.3x1036; men: HR: 1.46, 95%-CI: 1.341.58, p-value: 2.1x1019), among Europeans reporting vitamin D deficiencies (Europeans: HR: 2.31, 95%-CI: 2.132.51, p-value: 2.1x1087; non-Europeans: HR: 1.31, 95%-CI: 1.081.60, p-value=5.5x103), or among younger participants, e.g., disorders of magnesium metabolism and death with COVID-19 as a likely result of renal failure (age 65 years: HR: 42.98, 95%-CI: 20.1091.90, p-value: 3.0x1022; age >65 years: HR: 5.35, 95%-CI: 3.518.16, p-value: 5.9x1015).
We next derived a disease-disease network18 (Fig.3a) to understand, whether the large set of diseases associated with an increased risk for severe COVID-19 act independently or rather reflect an increased risk among participants suffering from multiple pre-existing conditions, i.e., multimorbidity. The network contained a total of 1381 diseases connected through 5212 edges based on non-random co-occurrence (Supplementary Data 5a, b). Diseases segregated into 31 communities being more strongly connected to each other compared to the rest of the network (Fig.3b, c).
a Disease disease network based on significant (p<4.8x108) positive partial correlations (two-sided). Nodes (diseases) are coloured by ICD-10 chapters and strength of partial correlation depicted by width of the edges. The underlying data can be found in Supplementary Data 5ac Same network, but only highlighting two disease communities strongly enriched for associations with severe COVID-19. d Hub score for the 30 diseases with highest values and associated association statistics, hazard ratios (rectangle) with 95%-confidence intervals (lines), from Cox-proportional hazard models (two-sided). Significant associations are indicated by filled boxes. Colours according to ICD-10 chapters. All underlying data can be found in Supplementary Data2 and 5b.
Two disease communities were consistently and strongly enriched for diseases associated with severe COVID-19. The first (e.g., OR: 5.20; p-value=2.2x1010; for severe respiratory failure) community was strongly enriched for circulatory (OR: 17.6; p-value: 4.4x1039) and respiratory (OR: 10.3; p-value: 7.8x1016) diseases, closely resembling the cardio-respiratory risk profile already described above (Fig.3b). The second community consisted of diverse endocrine (OR: 6.19; p-value: 1.9x1013) and circulatory disease (OR: 3.75; p-value: 5.4x108), and largely reflected the renal-diabetic risk profile (Fig.3c). Accordingly, for each disease acquired during lifetime within the latter disease community, participants risk increased by 18% and 20% to be hospitalised (HR: 1.18; 95%-CI: 1.171.18; p-value: p<10300) or die with COVID-19 (HR: 1.20; 1.191.20; p-value<10300), respectively.
Diseases increasing the risk for severe COVID-19, but not Long COVID further significantly correlated with hub status (e.g., hospitalisation: r=0.59; p-value: 2.8x10124) in the disease-disease network (Fig.3d), that is, diseases that connect a large cluster of diseases to the rest of the network and might hence be considered as multimorbidity hotspots. For example, acute renal failure, strongly associated with severe COVID-19 (Fig.3d), showed strong partial correlations with 30 other diseases and patients are hence prone to complex multimorbidity. However, the imperfect correlation between hub status and disease-association profiles indicates that certain forms of multimorbidity, such those related to secondary malignancies of lymph nodes, are possibly less related to severe COVID-19.
We next systematically characterised whether diseases identified to be associated with COVID-19 severity or Long COVID shared genetic similarity with host genetic susceptibility to severe COVID-19 to understand potential underlying causal mechanisms. We computed genetic correlation estimates for all 1128 disease COVID-19 outcome pairs and observed 75 pairs (6.6%) that showed evidence for significant (p<4.4x105) and directionally consistent genetic correlations (Fig.4 and Supplementary Data6), indicating a putatively causal link of any of 57 unique diseases on severe COVID-19. We did not observe evidence of convergence for Long COVID, which might likely be explained by the still low statistical power for the respective genome-wide association study13.
The first three panels show association statistics, hazard ratios (rectangle) and 95%-confidence interval (lines), for 57 diseases with evidence of convergence with genetic correlation analysis, that are shown in the last two panels (rectangle genetic correlation; lines 95%-confidence intervals). Disease have been grouped by ICD-10 chapters and coloured accordingly (see Figs.2 or 3 for legend). NOS = not elsewhere specified; All underlying data can be found in Supplementary Data1 (sample numbers), 2 and 6.
The diseases with consistent evidence from survival and genetic analysis included well-described risk-increasing effects of pre-existing endocrine (e.g., type 2 diabetes), respiratory (e.g., respiratory failure), or renal (e.g., chronic kidney disease) diseases, but also digestive (e.g., gastritis and duodenitis), or musculoskeletal (e.g., rheumatoid arthritis) diseases, and further symptoms of malaise and fatigue (rG=0.26; p-value=4.7106) and abdominal pain (rG=0.33; p=2.51011), as well as adverse reactions to drugs (e.g., poisoning by antibiotics: rG=0.38; p-value=2.2x106). Findings that collectively demonstrated the need for a comprehensive assessment of disease-risk beyond few, selected common chronic conditions.
Among the 41 diseases for which we had sufficient genetic instruments to perform more stringent Mendelian randomization (MR) analyses to assess causality, we observed only nominally significant (p<0.05) evidence for gout and hospitalisation (OR: 1.03; 95%-CI: 1.011.05, p-value: 0.03), as well as arthropathy not elsewhere specified (OR: 1.28; 95%-CI: 1.061.55; p-value: 0.02) and unspecified monoarthrtitis (OR: 1.21; 95%-CI: 1.041.41; p-value: 0.02) for severe COVID-19 (Supplementary Data7). While we might have been still underpowered for many diseases, this leaves the possibility that convergence of survival and genetic correlation analysis might, in part, be explained by shared risk factors.
To finally understand possible molecular mechanisms linking the diseasome to COVID-19, we systematically profiled disease associations across 49 independent genomic regions linked to COVID-19 or Long COVID. We observed strong and robust evidence of a genetic signal shared between severe COVID-19 and a total of 33 diseases at nine loci (posterior probability (PP)>80%) (Fig.5a and Supplementary Data8). Apart from known pleiotropic loci, such as ABO and FUT2 coding for blood group types, this included respiratory risk loci, albeit with contradicting effect estimates for three loci (Fig.5b). While COVID-19 risk increasing alleles at LZTFL1 and TRIM4 were consistently associated with a higher risk for viral pneumonia and post-inflammatory pulmonary fibrosis, respectively, risk-increasing alleles at MUC5B, NPNT, and PSMD3 were inversely associated with post-inflammatory pulmonary fibrosis and asthma. An observation that extended even beyond shared loci (Fig.5c) illustrating a general trend of phenotypic divergence of genetic effects on diseases that share pathological features with severe COVID-19.
a Network representation of significant (PP>80%) colocalization results. Loci are depicted as white rectangles and diseases as coloured nodes according to ICD-10 chapters. Edges represent strong evidence for colocalization, and solid lines indicate a risk-increasing effect of the COVID-19 risk increasing allele, whereas dashed lines indicate protective effects. Underlying data can be found in Supplementary Data8. b Forest plot displaying hazard ratios (rectangle) with 95%-confidence intervals (lines) for each variant and different COVID-19 and colocalising disease outcomes. Effect estimates for COVID-19 have been obtained from the COVID-19 Host Genetic Initiative and effect estimates for diseases in the present study. All estimates are derived from logistic regression models. c Heatmap of effect estimates across 49 independent genetic loci associated with increased risk for sever COVID-19 and corresponding effects on six selected traits that showed evidence of colocalization at least one other locus. Black rectangles indicate genome-wide significant effects (p<5108). NOS not elsewhere specified; All underlying data can be found in Supplementary Data1 and 8 or is given in the data availability statement.
A notable observation was the TYK2 locus that has previously been suggested to indicate the efficacy of successfully repurposed drugs for severe COVID-1929. Briefly, TYK2 encodes for tyrosine kinase 2 (TYK2) a protein partially targeted by Janus kinase (JAK) inhibitors like baricitinib, that have been approved for rheumatoid arthritis and successfully repurposed for severe COVID-19, although predating possible evidence from genetic studies30,31,32. Accordingly, we observed that the same genetic variant, rs34536443 (PP=99.8%), associated with the risk for severe COVID-19 was also associated with, amongst others, the risk of rheumatoid arthritis, but in opposing effect directions (Fig.5b). Rs34536443 is a loss-of-function missense variant (p.Pro1104Ala) for TYK2 and the functionally impairing minor C allele was associated with a 50% increased risk for severe COVID-19 (odds ratio: 1.50; 95%-CI: 1.40 1.62, p-value= 4.3x1029) but a 23% reduced risk for rheumatoid arthritis (odds ratio: 0.77; 95%-CI: 0.720.83; p-value=2.4x1012) as well as other autoimmune diseases, in particular psoriasis (Supplementary Data8). While the discrepancy between the success of the drug and genetic inference might be explained by the rather weak affinity of baricitinib for TYK233, patients undergoing trials with TYK2-inhibitors for psoriasis34 might be at an elevated risk for severe COVID-19. This observation seemingly aligns with studies on Tyk2-/- mouse models reporting an impaired immune response to viral infections35.
COVID-19 hospitalizations are on the rise in New York, and health officials are reminding everyone to continue following precautions to stay safe.
Eden Di Bianco just got over having COVID-19 for a third time. It came as a surprise after being very cautious due to being immunocompromised.
I tested positive on a home test when I started to feel some symptoms, but it was definitely a way rougher go than my second bout, Di Bianco said.
While the rest of her family stayed healthy, Di Bianco said she believes she was exposed to the disease at a baseball game they attended, keeping her bedridden for eight days.
It started with a headache and a sore throat, and Im hearing from a lot of other friends who've had it recently that the sore throat was really killer, and that was definitely my experience as well," Di Bianco said. "I had really intense sweats for about three days. I lost five pounds in a week. I had nausea, congestion, sneezing, which I have not had before, and just a general full body ache like someone threw me down a flight of stairs."
Di Bianco isnt sure which strain of COVID she may have had, but health expertssaynew strains of omicron, called the FLiRT variants, are spreading.
There's a surge that we knew would be coming, and we can't forget that this is kind of a cyclical thing that has been happening for the past few years, so we need to be prepared, said Neal Smoller, holistic pharmacist and owner of Village Apothecary.
Smoller said hes sold 30 times thenumberof COVID-19 tests in the past week than the one prior.
For the people that want to, again, be vigilant, to make sure that they are doing the best things wellness-wise for themselves. They are practicing all of the things that we've talked about since this started in 2020. Handwashing, social distancing, don't go into big crowds if you're nervous, wear masks and of course, get vaccinated as soon as you're eligible, Smoller said.
According to Gov. Kathy Hochuls office, COVID-19 hospitalization rates in New York are higher than this time last year but below what was experienced at this time in 2022.
Ive never been one to say that you can't live your life," Smoller said. "We have to live alongside COVID. I think that you should know that if you're going to get in an airplane, you run the risk of catching COVID. So, you might want to put a mask on, especially it's surging right now. But I don't think that that should deter anybody from their summer plans at all. I just think that you just need to be a little bit more cautious when you're out and about."
Di Bianco said her family plans on using caution throughout the rest of the summer with mostly outdoor activities planned.
Summer is actually a little bit more of a freeform time because we can enjoy being outdoors more, Di Bianco said.
Although Smoller said a new vaccine will be available in the fall, he said its still worth getting a booster now if those eligible havenot yetreceived one.
News Corp Australia uses software that manages crawler bot traffic on our websites. If you receive this message and are not a crawler bot (and are just a reader or subscriber), please try these steps first:
Your IP address is: 66.45.249.130 | Your reference number is: 0.6f24c317.1720676743.11887d48
News Corp Australia.
(Precision Vaccinations News)
CSL Seqirus today announced that it has commenced shipping its differentiated portfolio of influenza vaccines. This year, the company's influenza vaccines are being produced as trivalent influenza vaccineformulations, in compliance with the U.S. Food and Drug Administration'sdirective in 2024 to remove the B/Yamagata strain.
For the 2024-2025 influenza vaccine portfolio, CSL Seqirus isthe leadingmanufacturer offering a differentiated influenza vaccine option approved for use in people six months and older.
For example, FLUCELVAXis the first and only cell-based influenza vaccine indicated for use in people six months and older.
"Influenza continues to pose a significant threat, as evidenced by recent flu seasons," said Dr.Gregg Sylvester, Chief Health Officer, CSL Seqirus, in a press release on July 9, 2024.
"As we begin distributing influenza vaccines to healthcare providers throughout the U.S., it is imperative that we work to maintain high vaccination rates this season to help reduce the burden of influenza-related illnesses and the risk of severe outcomes."
CSL Seqirus is part of CSL, a global leader in the protection of public health and one of the largest influenza vaccine providers in the world.
On July 3, the U.S. Centers for Disease Control and Prevention (CDC) reported the fourth human case associated with an ongoing, multistate outbreak of bird flu in dairy cows this year. This marks the first case in Colorado and follows one case in Texas and two cases in Michigan, as CMM previously reported.
As with the previous cases, the infected individual is a worker on a dairy farm where cows tested positive for the bird flu virus. The person only reported eye symptoms and has since recovered.
The CDC has been watchinginfluenza surveillance systemsclosely, particularly in affected states, and reported no signs of unusual influenza activity in people.
In May, the CDC recommended farm workers wear personal protective equipment (PPE) to combat bird flu spread, but emphasized that the health risk to the U.S. general public remains low.
Still, last week Reuters reported the U.S. government awarded US$176 million to Moderna to advance bird flu vaccine development for humans. Late-stage testing for humans is expected to begin in 2025 and will focus on safety and immune response. Already, two dozen companies are working to develop a bird flu vaccine for cattle.
As of July 5, the U.S. Department of Agriculture has confirmed 140 cases in 12 states, with Idaho, Colorado, Michigan and Texas reporting the most cases. Since 2020, bird flu has become endemic in bird populations, causing an animal pandemic affecting at least 26 mammal species, according to a previous CMM report. Tests so far indicate that the virus detected in dairy cattle is the same clade that has been affecting wild birds and commercial poultry flocks.
BRIDGEWATER, N.J., July 10, 2024 /PRNewswire/ -- Sanofi today started shipping its first influenza (flu) vaccines across the U.S. in preparation for the 2024/25 flu season. Following this first shipment, additionalshipmentsof the full Sanofi flu vaccine portfolio will continue through October to healthcare provider offices, pharmacies and other immunizers to support fall immunization campaigns. With over 125 years of heritage in helping protect global public health,Sanofi is a world leader in vaccines, helping to vaccinate more than 500 million people annually.
ThomasGrenierHead of Vaccines, North America, Sanofi "Today, we began shipping flu vaccines for the upcoming season, a moment that underscores our long-standing commitment to providing global protection against disease. Getting a flu shot is imperative to not only help protect against flu infection, but also to help reduce the risks of its potentially severe complications, which can lead to hospitalizations, especially in those most vulnerable. Sanofi understands what these populations need out of their flu shots and works tirelessly from start to finish to provide proven and specific solutions."
All flu vaccines provided bySanofi to the US market are trivalent, meaning they offer protection against the current three strains of influenza (two influenza A strains and one influenza B strain).These strains were selected based on a collaborative review of influenza surveillance by the U.S. Food and Drug Administration (FDA), World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), among other public health experts, as the strains most likely to cause illness in the upcoming flu season.
Annual flu vaccination is one of the best ways to help protect against flu and its complications. Public health authorities worldwide reiterate their recommendations for eligible people to be vaccinated every year.
As one of the largest providers of influenza vaccines to the United States with a range of options,Sanofi meets immunization needs across the lifespan, from children as young as six months of age through adults 65 years of age and older. This year's 2024/25 U.S. influenza season portfolio includes Fluzone High-Dose (Influenza Vaccine), Flublok (Influenza Vaccine) and Fluzone (Influenza Vaccine).
Indication and Important Safety Information forFluzone High-Dose (Influenza Vaccine), Flublok (Influenza Vaccine) and Fluzone (Influenza Vaccine)
What areFluzone (Influenza Vaccine), Flublok (Influenza Vaccine), and Fluzone High-Dose (Influenza Vaccine)?
Fluzone, Flublok, and Fluzone High-Dose are vaccines indicated for the prevention of disease caused by influenza A and B strains contained in the vaccine. Fluzone is given to people 6 months of age and older. Flublok is given to people 18 years of age and older. Fluzone High-Dose is given to people 65 years of age and older.
IMPORTANT SAFETY INFORMATION FORFLUZONE (INFLUENZA VACCINE), FLUBLOK (INFLUENZA VACCINE), AND FLUZONE HIGH-DOSE (INFLUENZA VACCINE)
Fluzone, Flublok, or Fluzone High-Dose should not be given to anyone who has had a severe allergic reaction to any component of the vaccine (including eggs or egg products for Fluzone and Fluzone High-Dose). In addition, Fluzone and Fluzone High-Dose should not be given to anyone who has had a severe allergic reaction after a previous dose of any influenza vaccine.
Tell your health care provider if you have ever hadGuillain-Barr syndrome (severe muscle weakness) after a previous influenza vaccination.
If Fluzone, Flublok, or Fluzone High-Dose are given to people with a compromised immune system, including those receiving therapies that suppress the immune system, the immune response may be lower than expected.
Vaccination withFluzone, Flublok, or Fluzone High-Dose may not protect all people who receive the vaccine.
Fainting has occurred following vaccination withFluzone, Flublok, and Fluzone High-Dose. Procedures should be in place to avoid injury from fainting.
ForFluzone, in children 6 months through 8 years of age, the most common side effects were pain or tenderness and redness where you got the shot, irritability, drowsiness (6 month through 35 months), and muscle pain (3 years through 8 years). In adults 18 years through 64 years of age, the most common side effects were pain where you got the shot, headache, and muscle pain. In adults over 65 years of age, the most common side effects were pain where you got the shot, headache, muscle pain, and general discomfort.
For Flublok, in adults 18 through 64 years of age, the most common side effects were pain where you got the shot, headache, tiredness, and muscle pain. In adults 65 years of age and older, the most common side effects were pain where you got the shot, tiredness and headache.
ForFluzone High-Dose, in adults 65 years of age and older, the most common side effects were pain where you got the shot, muscle pain, tiredness, and headache.
ForFluzone, Flublok, and Fluzone High-Dose, other side effects may occur.
For more information, talk to your healthcare professional and refer to the full Prescribing and Patient information forFlublok, Fluzoneor Fluzone High-Dose.
About Sanofi We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY.
ContactsSandrine Guendoul|+ 33 6 25 09 14 25 |sandrine.guendoul@sanofi.com Evan Berland| +1 215 432 0234 |evan.berland@sanofi.com Timothy Gilbert|+ 1 516 521 2929 |timothy.gilbert@sanofi.com
Investor RelationsThomas Kudsk Larsen| +44 7545 513 693 |thomas.larsen@sanofi.comAliz Kaisserian| + 33 6 47 04 12 11 |alize.kaisserian@sanofi.comArnaud Delpine|+ 33 6 73 69 36 93 |arnaud.delepine@sanofi.comFelix Lauscher|+ 1 908 612 7239 |felix.lauscher@sanofi.comKeita Browne| + 1 781 249 1766 |keita.browne@sanofi.comNathalie Pham|+ 33 7 85 93 30 17 |nathalie.pham@sanofi.comTarik Elgoutni|+ 1 617 710 3587 |tarik.elgoutni@sanofi.com Thibaud Chtelet| + 33 6 80 80 89 90 | thibaud.chatelet@sanofi.com
Sanofi Forward-Looking StatementsThis media update contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2023. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
MAT-US-2406730-v1.0-07/2024
View original content:https://www.prnewswire.com/news-releases/sanofi-ships-us-influenza-vaccines-for-the-202425-season-302194084.html
SOURCE Sanofi
US pharmaceutical giant Pfizer on Tuesday said its chief scientific officer Mikael Dolsten, a key figure behind the development of the company's Covid-19 vaccine, would step down. Dolsten will be stepping down after over a 15-year career at the company. The drugmaker said it would start identifying a successor for Dolsten, a process which is expected to last several months. Dolsten joined Pfizer as part of the Wyeth acquisition in 2009, when he was named president of Worldwide Research and Development with the responsibility to lead all of Pfizer's research as well as development of all its treatments through mid-stage studies. Last year, Albert Bourla, Chief Executive Officer of US-based pharmaceutical giant Pfizer, encountered a series of tough questions about the efficacy of its Covid vaccine on the sidelines of the World Economic Forum meeting, but he repeatedly ignored the queries. Couple of Rebel News reporters named Ezra Levant and Avi Yemini were seen asking a lot of uncomfortable questions to the Pfizer CEO. Among the questions, he asked the CEO why the manufacturer kept the fact secret that its vaccine did not stop transmission of the virus. Rebel News posted a six-minute-long video of the confrontation on Twitter. In the video, the journalist grilled him about why Pfizer kept a secret about vaccines not stopping Covid transmission. "You (Pfizer) said it was 100% effective, then 90%, then 80%, then 70%, but we now know that the vaccines do not stop transmission. Why do you keep that secret?" the reporters asked. The Pfizer chief time and again ducked these questions, only to say "Thank you very much" and "Have a nice day". The reporters, however, kept on following the Pfizer chief even though he did not solicit a response. In another question, he was asked whether it was time to apologize to the world and to give refunds to the countries that bought vaccines that did not yield results. Are you not ashamed of what youve done in the last couple of years?" Yemini asked. A few weeks ago, the state of Kansas in the US filed a lawsuit against Pfizer, alleging that the pharmaceutical company engaged in deceptive practices regarding its Covid-19 vaccine. The lawsuit, filed in the District Court of Thomas County, accuses Pfizer of violating the Kansas Consumer Protection Act by making false claims about the vaccine's effectiveness while concealing potential risks. According to Kansas Attorney General Kris Kobach, a Republican, "Pfizer made multiple misleading statements to deceive the public about its vaccine at a time when Americans needed the truth." The lawsuit alleges that Pfizer hid evidence linking the vaccine to pregnancy complications, including miscarriage, as well as heart inflammation (myocarditis and pericarditis) shortly after the vaccine's rollout in early 2021. Pfizer denied the allegations, stating, "The representations made by Pfizer about its Covid-19 vaccine have been accurate and science-based."
Colorado health officials have confirmed a human case of the plague, the rare bacterial infection infamously known for killing tens of millions in 14th century Europe. Today, its easily treated with antibiotics.
The Centers for Disease Control and Prevention estimates there are seven human cases of plague per year in the U.S., and in February, Oregon officials reported it in a person who likely got it from their sick cat.
Surprised to hear the plague is still around? Heres what to know.
The bubonic plague is the most common form of the bacterial infection, which spreads naturally among rodents like prairie dogs and rats.
There are two other forms of the plague: septicemic plague (which spreads through the whole body) and pneumonic plague (which infects the lungs).
Bubonic plague causes painfully swollen lymph nodes that are most commonly found in the groin, armpit and neck, called buboes. It will often advance and turn into the other two forms of plague if untreated.
Other symptoms of the plague include sudden high fever and chills, headaches, and pain in the abdomen, legs and arms, according to the Cleveland Clinic.
The bacteria is transmitted through the bites of infected fleas, which spread it between rodents, pets and humans.
People can also get plague through touching infected bodily fluids, so health experts recommend taking extra care when handling dead or sick animals. The plague can also spread through the respiratory droplets of a patient who has pneumonic plague.
Pneumonic plague is the most deadly and easiest to spread, with a nearly 100% fatality rate untreated, said Lisa Morici, a microbiologist and immunologist at the Tulane University School of Medicine.
In the U.S., most cases happen in rural areas of northern New Mexico, northern Arizona, southern Colorado, California, southern Oregon and far western Nevada, according to the CDC.
Worldwide, plague is found the most in Congo, Madagascar and Peru, according to the World Health Organization.
The plague was never eradicated, but weve gotten better at preventing its spread and treating it in humans.
When treated early with antibiotics, the plague can be cured. The key is to get to a doctor fast -- otherwise the plague can be deadly.
And, as the old adage goes, prevention is better than a cure.
Keeping areas around the home clear of debris and other things that can attract rodents can lower the risk of infection, as can making sure pets are up to date on flea treatments. When hunting, camping or otherwise spending time outdoors, the CDC recommends using a bug spray with DEET to keep fleas and other disease-spreading pests away.
Yes, but the WHO only recommends it for people who are at high risk of infection, like laboratory and health care workers. Theres no plague vaccine available in the U.S.
Morici said there is need for more research, because while the vaccines used in other parts of the world work against bubonic plague, there isnt strong evidence to show they protect against the pneumonic form of plague.
Testing a plague vaccine would be ethically and logistically difficult, she said.
Because the bubonic form is quite treatable with antibiotics and also quite rare you dont see thousands and thousands of cases of plague a year theres just not a huge market for a plague vaccine at this point in time, Morici said.
The Associated Press Health and Science Department receives support from the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
